It refers to a fixed dose of drug synthesis, including the combination of dipropylene glycol and acetylhydrochloric acid (ASA), as well as a target country of electronic angotensine II, as a mixed preparation for simultaneous, separation and sequential use. It also refers to the use of this synthesis to prevent cerebrovascular accidents or secondary cerebrovascular accidents, or to reduce the risk of cerebrovascular accidents in patients.
展开▼